Opyl Ltd. (AU:PKY)
ASX:PKY
Want to see AU:PKY full AI Analyst Report?
Top Page
Opyl Ltd.
(Sydney:PKY)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.05
▲(70.00% Upside)
Action:Reiterated
Date:05/05/26
The score is primarily constrained by very weak financial fundamentals (sharp revenue contraction, persistent losses, negative equity, and ongoing cash burn). Technicals provide some offset with strong recent momentum, but the extremely overbought RSI increases short-term risk. Valuation remains challenged due to loss-making status and no dividend.
Positive Factors
AI-driven clinical trial platform
Opyl’s core focus on AI/ML for clinical trials is a durable strategic asset: algorithmic platforms can create defensible data moats and recurrent utility for sponsors, improving patient ID and trial efficiency. Over months this supports sticky B2B relationships and product-led scaling.
Negative Factors
Severe revenue contraction
An ~86% year‑over‑year revenue drop is structurally damaging: it reduces commercial traction, undermines recurring revenue baselines, and lengthens the path to scale. Recovery will likely require sustained new sales or partnerships, increasing funding needs over months.
Read all positive and negative factors
Positive Factors
Negative Factors
AI-driven clinical trial platform
Opyl’s core focus on AI/ML for clinical trials is a durable strategic asset: algorithmic platforms can create defensible data moats and recurrent utility for sponsors, improving patient ID and trial efficiency. Over months this supports sticky B2B relationships and product-led scaling.
Read all positive factors
Opyl Ltd. (PKY) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$24.89M
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)―
Beta (1Y)1.67
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding607,077,760
10 Day Avg. Volume406,454
30 Day Avg. Volume1,132,050
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-21.63
Price to Sales (P/S)208.90
P/FCF Ratio-4.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Opyl Ltd. Business Overview & Revenue Model
Company Description
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success predict...
How the Company Makes Money
Opyl’s revenue model is based on commercialising its technology and platforms through business-to-business arrangements. Key potential revenue streams include (i) subscription or licensing fees for access to its software platforms and analytics ca...
Opyl Ltd. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -3.95K | 27.78K | 397.64K | 397.64K | 617.91K | 902.41K |
| Gross Profit | -490.89K | -778.89K | -1.40M | -1.86M | -930.36K | -809.62K |
| EBITDA | -1.89M | -1.66M | -2.68M | -1.70M | -2.27M | -1.14M |
| Net Income | -1.44M | -1.45M | -3.13M | -3.13M | -1.73M | -2.09M |
Balance Sheet | ||||||
| Total Assets | 881.60K | 513.28K | 411.60K | 411.60K | 709.58K | 979.22K |
| Cash, Cash Equivalents and Short-Term Investments | 580.84K | 436.90K | 374.64K | 452.88K | 786.33K | 2.32M |
| Total Debt | 0.00 | 411.73K | 0.00 | 300.00K | 300.00K | 0.00 |
| Total Liabilities | 356.22K | 781.65K | 501.76K | 501.76K | 712.21K | 314.75K |
| Stockholders Equity | 525.39K | -268.37K | -90.16K | -403.59K | 267.01K | 2.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.12M | -1.29M | -2.07M | -1.37M | -1.53M | -918.13K |
| Operating Cash Flow | -1.12M | -1.28M | -2.06M | -1.36M | -1.52M | -903.65K |
| Investing Cash Flow | -332.70K | -334.02K | -17.71K | -2.22K | -2.22K | -14.48K |
| Financing Cash Flow | 1.44M | 1.35M | 2.00M | 1.03M | 1.03M | 2.43M |
Opyl Ltd. Technical Analysis
Positive
0.03
Price Trends
0.03
Positive
0.03
Positive
0.02
Positive
Market Momentum
<0.01
Positive
51.80
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PKY, the sentiment is Positive. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.03, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.80 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PKY.
Opyl Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$18.59M | -2.48 | -578.72% | ― | 43.55% | 26.03% | |
44 Neutral | AU$24.89M | -1.71 | -1122.02% | ― | ― | ― | |
43 Neutral | AU$58.60M | -6.64 | -59.96% | ― | ― | ― | |
42 Neutral | AU$7.56M | -0.96 | 152.58% | ― | -57.91% | -9.02% | |
41 Neutral | AU$3.59M | -1.98 | 15.41% | ― | -5.76% | 8.00% |
* Healthcare Sector Average
AU:PKY
Opyl Ltd.
0.04
0.02
115.79%
AU:GLH
Global Health Limited
0.06
-0.02
-23.75%
AU:SHG
Singular Health Group Ltd
0.19
-0.12
-39.34%
AU:HIQ
HitIQ Limited
0.01
-0.01
-52.38%
AU:ICR
InteliCare Holdings Limited
0.03
0.01
85.71%
Opyl Ltd. Corporate Events
Pathkey.AI Names Defence-Tech Veteran Andrew Farnsworth CEO to Drive Applied AI Expansion
May 10, 2026
Pathkey.AI has appointed defence and AI systems specialist Andrew Farnsworth as chief executive officer, formalising a role he has effectively played during a six-month strategic review that reframed the company as an applied AI platform provider ...
Pathkey expands agentic AI footprint with Chipforge deal and TrialKey wins
Apr 30, 2026
Pathkey’s March quarter update shows continued investment in developing TrialKey as a scalable, AI-driven tool for clinical trial design, adding a Criteria Optimiser that uses agentic AI workflows to generate and rank protocol options under ...
PathKey.AI links share price surge to confidential Chipforge acquisition talks
Apr 29, 2026
PathKey.AI has responded to an ASX price query after its shares rose from $0.03 to $0.046 and trading volumes spiked in late April. The company disclosed it has been in confidential talks to acquire Singapore-based Chipforge Pte Ltd, which holds a...
Pathkey.AI Shares Halted Ahead of Price Query Response and Acquisition News
Apr 27, 2026
Pathkey.AI has requested and been granted a trading halt on its securities by the ASX, with the suspension to remain in place until the earlier of 29 April 2026 or the release of a pending market announcement. The halt is tied to the company prepa...
Pathkey.AI switches share registry provider to Xcend
Mar 27, 2026
Pathkey.AI Ltd has announced a change in its share registry services, transferring responsibility from Automic Registry Services to Xcend Pty Ltd, effective 13 April 2026. Automic will cease as registry provider on 10 April 2026, with XCEND to man...
Pathkey.AI shifts registered office to Sydney CBD while maintaining operations
Mar 13, 2026
Pathkey.AI Ltd has relocated its registered office and principal place of business to Level 12, 347 Kent Street, Sydney, while confirming that all other company details remain unchanged. The move signals an administrative change rather than a stra...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.